Argenx

This study continues testing an experimental drug called ARGX-117 in adults with multifocal motor neuropathy (MMN), a rare condition that causes muscle weakness. It follows 51 participants from a previous trial to check the drug's long-term safety and whether it helps maintain mu…

This study is testing whether a medication called efgartigimod, given as an injection, can help adults with ocular myasthenia gravis. Ocular myasthenia gravis causes weakness in the eye muscles, leading to problems like double vision and drooping eyelids. For the first 7 weeks, h…

This study follows up on previous participants to check the long-term safety and effectiveness of efgartigimod injections for inflammatory muscle diseases like dermatomyositis and polymyositis. About 240 adults who completed an earlier trial will receive the treatment for up to 5…

This study is testing an investigational drug called ARGX-117 to see if it can help a newly transplanted kidney from a deceased donor start working properly sooner. It will involve about 103 adults who have just received a kidney transplant and are at risk for a slow-starting kid…

This study is testing if adults with a chronic nerve disease called CIDP can safely switch from their current intravenous (IV) treatment to a newer medication given as a shot under the skin. The goal is to see if patients can successfully make the switch and continue the new trea…

This study aims to check the long-term safety of a drug called efgartigimod in children with generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness. It is open only to children who have already received the drug in earlier, related clinical trials. The …

This study is testing a new drug called empasiprubart to see if it is safe and can help control the symptoms of dermatomyositis, a rare autoimmune disease that causes muscle weakness and skin rashes. About 3 adults with active dermatomyositis will receive either the new drug or a…

This study is testing an investigational drug called ARGX-119 in adults with ALS (amyotrophic lateral sclerosis). The main goals are to check the drug's safety and see if it can help slow the loss of muscle function. About 60 participants will receive different doses of the drug …

This trial is testing the long-term safety and effectiveness of a medication called efgartigimod, given as an injection under the skin, for adults with primary immune thrombocytopenia (ITP). The study aims to see if the treatment can help keep platelet counts at a safer level ove…

This study is testing whether an intravenous drug called efgartigimod is effective and safe for adults with a specific, hard-to-treat form of generalized myasthenia Gravis (gMG). About 119 participants will be randomly assigned to receive either the drug or a placebo for part of …

This study aims to better understand how multifocal motor neuropathy (MMN) affects people's daily lives and health over time. It will follow 413 adults who already have a diagnosis of MMN, tracking their symptoms, quality of life, and use of healthcare services. The study does no…